Rutian Li
Overview
Explore the profile of Rutian Li including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
813
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yen Y, Zhang Z, Chen A, Qiu Y, Liu Q, Wang Q, et al.
J Nanobiotechnology
. 2025 Feb;
23(1):124.
PMID: 39972327
Immune checkpoint inhibitors (ICIs) have revolutionized lung cancer treatment, yet resistance remains a challenge. Co-inhibition of PD-1/PD-L1 and TGF-β shows promise but faces limited efficacy and systemic toxicity. We developed...
2.
Bei Y, Huang Y, Wu N, Li Y, Xu R, Liu B, et al.
EMBO Mol Med
. 2025 Jan;
17(2):365-383.
PMID: 39748060
The adoptive transfer of TCR-T cells specific to neoantigens preferentially exhibits potent cytotoxicity to tumor cells and has shown promising efficacy in various preclinical human cancers. In this study, we...
3.
Li C, Lei D, Huang Y, Jing Y, Wang W, Cen L, et al.
Mater Today Bio
. 2024 Oct;
29:101281.
PMID: 39430571
Ginsenoside Rh2 (G-Rh2) is a vital bioactive compound in Traditional Chinese Medicine, celebrated for its strong pharmacological properties, particularly its potent antitumor effects. However, its poor water solubility and limited...
4.
Diao S, Zhang Z, Zhao S, Li Q, Zhang X, Yang X, et al.
Adv Sci (Weinh)
. 2024 Oct;
11(45):e2409833.
PMID: 39401431
Photodynamic immunotherapy which combines photodynamic therapy with immunotherapy has become an important and effective method for the treatment of cancer. However, most cancer photodynamic immunotherapeutic systems are not able to...
5.
Li Y, Wang Q, Li L, Yuan S, Chen H, Li R, et al.
Chin Med J (Engl)
. 2024 Sep;
137(21):2627-2629.
PMID: 39307931
No abstract available.
6.
Lu H, Wang J, Chen Z, Wang J, Jiang Y, Xia Z, et al.
Adv Sci (Weinh)
. 2024 Sep;
11(41):e2403542.
PMID: 39264262
Despite the widespread adoption of emergency coronary reperfusion therapy, reperfusion-induced myocardial injury remains a challenging issue in clinical practice. Following myocardial reperfusion, S100A8/A9 molecules are considered pivotal in initiating and...
7.
Sun M, Shi T, Tuerhong S, Li M, Wang Q, Lu C, et al.
Adv Healthc Mater
. 2024 Jul;
13(28):e2401635.
PMID: 39054611
In situ vaccination is an attractive type of cancer immunotherapy, and methods of persistently dispersing immune agonists throughout the entire tumor are crucial for maximizing their therapeutic efficacy. Based on...
8.
Dai J, Zhu J, Zhu L, Wang X, Bao J, Chen X, et al.
Future Oncol
. 2024 Jul;
20(20):1393-1400.
PMID: 39034683
vaccination, a kind of therapeutic cancer vaccine, can be realized by radiotherapy and intratumoral immune injection. This study combines intratumoral injection, radiotherapy and PD-1 blockade for synergistic antitumor effect. Patients...
9.
Wang Q, Peng R, Qi H, Xu R, Liu W, Meng F, et al.
MedComm (2020)
. 2024 Jul;
5(7):e618.
PMID: 38974711
T-cell receptor (TCR) engineered T-cell therapy, unlike chimeric antigen receptor T-cell therapy, relies on the inherent ability of TCRs to detect a wider variety of antigenic epitopes, such as protein...
10.
Shi T, Sun M, Tuerhong S, Li M, Wang J, Wang Y, et al.
Biomaterials
. 2024 May;
309:122607.
PMID: 38759487
The use of CAR-T cells in treating solid tumors frequently faces significant challenges, mainly due to the heterogeneity of tumor antigens. This study assessed the efficacy of an acidity-targeting transition-aided...